Combined Inhibition of MEK and Plk1 Has Synergistic Antitumor Activity in NRAS Mutant Melanoma
Open Access
- 1 October 2015
- journal article
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 135 (10) , 2475-2483
Abstract
No abstract availableKeywords
This publication has 57 references indexed in Scilit:
- The Many Faces of C/EBPδ and their Relevance for Inflammation and CancerInternational Journal of Biological Sciences, 2013
- Interplay between MEK-ERK signaling, cyclin D1, and cyclin-dependent kinase 5 regulates cell cycle reentry and apoptosis of neuronsMolecular Biology of the Cell, 2012
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics DataCancer Discovery, 2012
- Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR PathwayPLOS ONE, 2011
- Dissection of RAS downstream pathways in melanomagenesis: a role for Ral in transformationOncogene, 2010
- Targeted Depletion of Polo-Like Kinase (Plk) 1 Through Lentiviral shRNA or a Small-Molecule Inhibitor Causes Mitotic Catastrophe and Induction of Apoptosis in Human Melanoma CellsJournal of Investigative Dermatology, 2009
- The combined status of ATM and p53 link tumor development with therapeutic responseGenes & Development, 2009
- Combined Targeting of BRAF and CRAF or BRAF and PI3K Effector Pathways Is Required for Efficacy in NRAS Mutant TumorsPLOS ONE, 2009
- A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras OncogeneCell, 2009
- Ras proteins: paradigms for compartmentalised and isoform-specific signallingCellular and Molecular Life Sciences, 2007